Patents by Inventor Joerg Regula
Joerg Regula has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952421Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.Type: GrantFiled: October 8, 2015Date of Patent: April 9, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
-
Publication number: 20230220079Abstract: Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.Type: ApplicationFiled: March 13, 2023Publication date: July 13, 2023Inventors: Christian BEIL, Jochen BENINGA, Joerg BIRKENFELD, Gary J. NABEL, Huawei QIU, Ercole RAO, Joerg REGULA, Edward SEUNG, Ronnie WEI, Lan WU, Zhen XING, Ling XU, Zhi-Yong YANG
-
Patent number: 11613576Abstract: Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.Type: GrantFiled: April 8, 2020Date of Patent: March 28, 2023Assignee: SANOFIInventors: Christian Beil, Jochen Beninga, Joerg Birkenfeld, Gary J. Nabel, Huawei Qiu, Ercole Rao, Joerg Regula, Edward Seung, Ronnie Wei, Lan Wu, Zhen Xing, Ling Xu, Zhi-Yong Yang, Béatrice Cameron, Tarik Dabdoubi, Cendrine Lemoine, Catherine Prades
-
Publication number: 20210395355Abstract: Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.Type: ApplicationFiled: July 12, 2021Publication date: December 23, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Guido Hartmann, Joerg Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
-
Publication number: 20200399369Abstract: Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.Type: ApplicationFiled: April 8, 2020Publication date: December 24, 2020Inventors: Mangaiarkarasi ASOKAN, Christian BEIL, Jochen BENINGA, Joerg BIRKENFELD, Mark CONNORS, Richard A. KOUP, Young Do KWON, Peter D. KWONG, Qingbo LIU, Paolo LUSSO, John R. MASCOLA, Gary J. NABEL, Amarendra PEGU, Huawei QIU, Ercole RAO, Joerg REGULA, Edward SEUNG, Ronnie WEI, Lan WU, Zhen XING, Ling XU, Zhi-Yong YANG, Béatrice Cameron, Tarik Dabdoubi, Cendrine Lemoine, Catherine Prades
-
Patent number: 10253104Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3?, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.Type: GrantFiled: August 3, 2015Date of Patent: April 9, 2019Assignee: ENGMAB AGInventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Lydia Jasmin Hanisch, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
-
Publication number: 20170306036Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3epsilon, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), r aspartic acid (D) (numbering according to Kabat). Also the manufacture and use of said antibody.Type: ApplicationFiled: August 3, 2015Publication date: October 26, 2017Applicant: ENGMAB AGInventors: Minh Diem VU, Klaus STREIN, Oliver AST, Marina BACAC, Lydia Jasmin HANISCH, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Samuel MOSER, Ramona MURR, Pablo UMANA, Sabine JUNG-IMHOF, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg REGULA, Wolfgang SCHAEFER
-
Publication number: 20170306044Abstract: Bispecific antibodies against CD3epsilon and ROR1 are useful for use in the treatmentof ovarian cancer.Type: ApplicationFiled: October 8, 2015Publication date: October 26, 2017Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RALF HOSSE, CHRISTIAN KLEIN, EKKEHARD MOESSNER, SAMUEL MOSER, RAMONA MURR, PABLO UMANA, SABINE JUNG-IMHOF, STEFAN kLOSTERMANN, MICHAEL MOLHOJ, JOERG REGULA, WOLFGANG SCHAEFER
-
Publication number: 20170306018Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.Type: ApplicationFiled: October 8, 2015Publication date: October 26, 2017Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RALF HOSSE, CHRISTIAN KLEIN, EKKEHARD MOESSNER, SAMUEL MOSER, RAMONA MURR, PABLO UMANA, SABINE JUNG-IMHOF, STEFAN KLOSTERMANN, MICHAEL MOLHOJ, JOERG REGULA, WOLFGANG SCHAEFER
-
Publication number: 20120322732Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.Type: ApplicationFiled: July 18, 2012Publication date: December 20, 2012Inventors: Beat Amrein, Stefan Foser, Kurt Lang, Friedrich Metzger, Joerg Regula, Andreas Schaubmar, Friederike Hesse, Klaus-Peter Kuenkele, Martin Lanzendoerfer
-
Publication number: 20110009317Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.Type: ApplicationFiled: June 2, 2010Publication date: January 13, 2011Inventors: Beat Amrein, Stefan Foser, Kurt Long, Friedrich Metzger, Joerg Regula, Andreas Schaubmar, Friederike Hesse, Klaus-Peter Kuenkele, Martin Lanzendoerfer
-
Publication number: 20060263356Abstract: An antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.Type: ApplicationFiled: January 3, 2006Publication date: November 23, 2006Inventors: Josef Endl, Maria Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Regula, Ralf Schumacher, Stefan Seeber, Jan stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
-
Publication number: 20060154865Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.Type: ApplicationFiled: December 20, 2005Publication date: July 13, 2006Inventors: Beat Amrein, Stefan Foser, Kurt Lang, Friedrich Metzger, Joerg Regula, Andreas Schaubmar, Friederike Hesse, Klaus-Peter Kuenkele, Martin Lanzendoerfer